Ask AI
ProCE Banner Activity

TROPION-Lung02: Phase I Study of First-line Datopotamab Deruxtecan + Pembrolizumab ± Platinum Chemotherapy in Advanced NSCLC

Conference Coverage
Slideset

Results from the final analysis from TROPION-Lung02 evaluating first-line Dato-DXd plus pembrolizumab with or without platinum chemotherapy in patients with advanced NSCLC suggest encouraging efficacy and safety in support of ongoing clinical development.

Released: June 03, 2025

Expiration: December 02, 2025

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo, Inc, Genentech, a member of the Roche Group, and PharmaMar.

AstraZeneca

Boehringer Ingelheim Pharmaceuticals, Inc.

Daiichi Sankyo, Inc.

Genentech, a member of the Roche Group

PharmaMar